Review



egfr spiking  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Miltenyi Biotec egfr spiking
    Assessment of different blood collection tubes for <t>EGFR</t> assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of <t>numerous</t> <t>DAPI</t> + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.
    Egfr Spiking, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr spiking/product/Miltenyi Biotec
    Average 94 stars, based on 30 article reviews
    egfr spiking - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients"

    Article Title: Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2020.572895

    Assessment of different blood collection tubes for EGFR assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of numerous DAPI + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.
    Figure Legend Snippet: Assessment of different blood collection tubes for EGFR assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of numerous DAPI + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.

    Techniques Used: Clinical Proteomics, Mutagenesis



    Similar Products

    egfr spiking  (Miltenyi Biotec)
    94
    Miltenyi Biotec egfr spiking
    Assessment of different blood collection tubes for <t>EGFR</t> assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of <t>numerous</t> <t>DAPI</t> + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.
    Egfr Spiking, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr spiking/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    egfr spiking - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    original sars cov 2 spike pseudotyped lentivirus  (BPS Bioscience)
    91
    BPS Bioscience original sars cov 2 spike pseudotyped lentivirus
    Assessment of different blood collection tubes for <t>EGFR</t> assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of <t>numerous</t> <t>DAPI</t> + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.
    Original Sars Cov 2 Spike Pseudotyped Lentivirus, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/original sars cov 2 spike pseudotyped lentivirus/product/BPS Bioscience
    Average 91 stars, based on 1 article reviews
    original sars cov 2 spike pseudotyped lentivirus - by Bioz Stars, 2026-03
    91/100 stars
    		  Buy from Supplier
    rabbit polyclonal antibody against egfr  (Proteintech)
    96
    Proteintech rabbit polyclonal antibody against egfr
    Assessment of different blood collection tubes for <t>EGFR</t> assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of <t>numerous</t> <t>DAPI</t> + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.
    Rabbit Polyclonal Antibody Against Egfr, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal antibody against egfr/product/Proteintech
    Average 96 stars, based on 1 article reviews
    rabbit polyclonal antibody against egfr - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Assessment of different blood collection tubes for EGFR assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of numerous DAPI + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.

    Journal: Frontiers in Oncology

    Article Title: Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

    doi: 10.3389/fonc.2020.572895

    Figure Lengend Snippet: Assessment of different blood collection tubes for EGFR assays on cfDNA and CTC DNA after 24 and 48 h of blood storage. (A) Overall performance of the different BCTs. LBgard is identified as the preferred BCT as opposed to EDTA, which performance significantly worsens over the storage duration. (B) Initial blood cell viability in the plasma-depleted blood sample, before VTX-1 processing. (C) Presence of numerous DAPI + debris, i.e., nucleus from dead cells, in the VTX-1 output from EDTA BCTs after 48 h. (D) cfDNA yield from the plasma workflow. (E) Cell DNA yield from the cell workflow after VTX-1 processing. (F) EGFR mutation detection for cfDNA and CTC DNA, at Day 0, 1, and 2. All pictures are original.

    Article Snippet: After a centrifugation (600 g , 1 min, RT) and aspiration of the supernatant, cells were fixed with 2% PFA (Electron Microscopy Sciences #157-4) for 10 min, permeabilized with 0.2% volume/volume Triton X-100 (Research Products International Corp) and 5% Goat Serum (Invitrogen) for 7 min, blocked with 10% Goat Serum for 30 min, and immunostained. (i) For the experiments assessing the different blood collection tubes , immunostaining was performed using antibodies directed against cytokeratins (CK) (FITC, Clone CAM 5.2, BD Biosciences #347653; Clone CK3-6H5 Miltenyi Biotec #130080101), against CD45 (PE, Clone HI30, BD Pharmingen #555483) and counterstained with DAPI (Molecular Probes #D3571). (ii) For all EGFR spiking experiments and patient samples , cells were stained with anti-CK FITC (Clone CAM 5.2, BD Biosciences, #347653; Clone CK3-6H5, MACS Miltenyi, #130-080-101; Clone AE1/AE3, eBioscience, #53-9003-82), anti-Vimentin AF647 (Clone V9, Abcam, #195878), anti-N-Cadherin AF647 (Clone EPR1791-4, Abcam, #195186) and anti-CD45 PE (Clone HI30, BD Biosciences, #555483) and counterstained with DAPI.

    Techniques: Clinical Proteomics, Mutagenesis